Phase 1 study of mebendazole therapy for refractory/progressive or recurrent pediatric brain tumors

Kenneth J. Cohen(Hospital for Sick Children), Eric H. Raabe(Johns Hopkins University), Gregory J. Riggins(Unknown), Michael A. Koldobskiy(Johns Hopkins University), Stacie Stapleton(Johns Hopkins University)
Neuro-Oncology Practice
June 6, 2025
10.1093/nop/npaf060
Cited by 3

Related Papers

Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome
|Cell|1991|3.5k
<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
|Proceedings of the National Academy of Sciences|2013|1.4k
Analysis of human transcriptomes
|Nature Genetics|1999|789